Galectin Therapeutics Inc.

NASDAQ:GALT

Biotechnology

Healthcare
$2.98 +1.62%

+$0.05 today

Market cap
$196.25M
Beta
0.49
P/E (TTM)
-7.1
EPS (TTM)
-$0.40
52W Low $1.85High $7.13

Volume 0.23M

Average 0.32M

GALT Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Galectin Therapeutics Inc.NASDAQ: GALT

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $5.05M (cash outflow) fell 47.6% year over year, behind the -41.9% change in trailing-twelve-month net income. Sequentially, it fell 8.3% from the prior quarter. Over 3 fiscal years it compounded at -7.4% a year.

Context

  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 1 analysts of -$23.64M (-23.3%) for the fiscal year ending Dec 2026, a step up from the -34.5% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$5.05M-8.3% QoQ
Last fiscal yearDec 2025
-$30.84M-34.5% YoY
LTMMar 2026
-$26.25M-41.9% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-47.6%-21.3%+26.3 pp
1 year-34.5%-23.3%+11.1 pp
3-year CAGR-7.4%+30.0%+37.3 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(30.84M) USD
Year-over-year change
+34.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How GALT compares with its peers on the latest reported figures

  • GALT's LTM Mar 2026 net income of $26.25M is the smallest of the 10 companies compared; the peer median is $91.08M.
  • Its year-over-year change of -41.9% is the lowest of 9, against a peer median of +21.4%.
  • Over three fiscal years its annual growth of -7.4% compares with a peer median of +8.1%.
GALT Competitors Peer median
Net Income for GALT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$209.38M -18.9%+0.2%—
ENGNenGene Holdings Inc.LTM Apr 2026$126.85M +58.8%+68.6%—
AURAAura Biosciences, Inc.LTM Mar 2026$112.39M +18.7%+21.8%—
QSIQuantum-Si incorporatedLTM Mar 2026$103.82M +3.1%-8.5%5605.9%
ALTAltimmune, Inc.LTM Mar 2026$91.08M +0.9%+1.3%253002.8%
DSGNDesign Therapeutics, Inc.LTM Mar 2026$69.71M +24.0%+3.3%—
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$42.63M +34.3%+8.1%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$39.17M —+20.7%—
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$35.1M +30.0%+33.8%—
GALTGalectin Therapeutics Inc.LTM Mar 2026$26.25M -41.9%-7.4%—
Peer median (excluding GALT) $91.08M+21.4%+8.1%129304.3%

Competitors are the stored peer set for GALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(30.53M)(38.78M)(41.07M)(47.05M)(30.84M)
Depreciation & Amortization41K32K33K37K53K
Deferred Income Tax00000
Stock-Based Compensation2.08M2.87M2.26M2.45M1.66M
Change in Working Capital3.75M4.97M4.68M2.28M609K
Accounts Receivables00000
Inventory00000
Accounts Payables3.69M4.24M2.67M(2.07M)(6.04M)
Other Working Capital65K724K2.01M4.36M6.65M
Other Non-Cash Items351K(147K)1.13M512K4.64M
Operating Cash Flow(24.31M)(31.06M)(32.97M)(41.77M)(23.88M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment30M10M30M30M21M
Common Stock Issued6.81M001.23M5.48M
Common Stock Repurchased00000
Dividends Paid(171K)00(91K)0
Other Financing Activities171K010.03M91K0
Financing Cash Flow36.81M10M40.03M31.23M26.48M
Effect of Forex Changes00000
Net Change in Cash12.51M(21.06M)7.07M(10.54M)2.6M
Free Cash Flow(24.31M)(31.06M)(32.97M)(41.77M)(23.88M)

Galectin Therapeutics Inc.

NASDAQ:GALT

Intrinsic Alpha fair value

Locked

Current Price

$2.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.